X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (29) 29
ntrk (25) 25
oncology (21) 21
humans (17) 17
larotrectinib (14) 14
pathology (13) 13
tumors (13) 13
etv6-ntrk3 gene fusion (12) 12
ntrk fusion (12) 12
cancer (10) 10
entrectinib (9) 9
infantile fibrosarcoma (9) 9
acquired-resistance (8) 8
female (8) 8
gene fusion (7) 7
immunohistochemistry (7) 7
male (7) 7
pan-trk (7) 7
tropomyosin (7) 7
fibrosarcoma (6) 6
health aspects (6) 6
rearrangements (6) 6
surgery (6) 6
adult (5) 5
alk (5) 5
alk inhibitor (5) 5
expression (5) 5
gene fusions (5) 5
genetic aspects (5) 5
hybridization (5) 5
mutation (5) 5
pediatrics (5) 5
precision medicine (5) 5
receptor, trka - genetics (5) 5
review (5) 5
ros1 (5) 5
sarcoma (5) 5
subset (5) 5
targeted therapy (5) 5
trk inhibitor (5) 5
animals (4) 4
braf (4) 4
development and progression (4) 4
egfr (4) 4
fusion (4) 4
loxo-101 (4) 4
lung cancer (4) 4
lung neoplasms - drug therapy (4) 4
medicine & public health (4) 4
middle aged (4) 4
non-small cell lung cancer (4) 4
nsclc (4) 4
oncogene proteins, fusion - genetics (4) 4
open-label (4) 4
patient (4) 4
pharmacology & pharmacy (4) 4
pyrimidines - therapeutic use (4) 4
receptor (4) 4
ret (4) 4
secretory carcinoma (4) 4
trk (4) 4
adolescent (3) 3
article (3) 3
brain neoplasms - genetics (3) 3
brain neoplasms - pathology (3) 3
breast-cancer (3) 3
carcinoma (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
care and treatment (3) 3
cell biology (3) 3
chemotherapy (3) 3
child, preschool (3) 3
children (3) 3
clinical neurology (3) 3
clinical trials (3) 3
congenital mesoblastic nephroma (3) 3
genes (3) 3
hematology (3) 3
infant (3) 3
inhibitor entrectinib (3) 3
kinases (3) 3
landscape (3) 3
lung neoplasms - genetics (3) 3
magnetic resonance imaging (3) 3
metastases (3) 3
nervous system (3) 3
neurosciences (3) 3
ntrk gene fusions (3) 3
oncogene (3) 3
pediatric (3) 3
phosphotransferases (3) 3
proteins (3) 3
pyrazoles - therapeutic use (3) 3
receptor, trkb - genetics (3) 3
receptor, trkc - genetics (3) 3
resistance (3) 3
signal transduction (3) 3
trk receptors (3) 3
tyrosine kinase inhibitor (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Pathology - Research and Practice, ISSN 0344-0338, 10/2019, Volume 215, Issue 10, p. 152572
The neurotrophic tyrosine receptor kinases ( ) play an important role in the development and function of the nervous system. Fusions involving and a wide range... 
Tumor agnostic | Neurotrophic tyrosine receptor kinases | NTRK | NTRK fusions | TRK inhibitor
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 10/2019, Volume 43, Issue 10, pp. 1384 - 1391
A major breakthrough in the classification of soft tissue tumors has been the recent identification of NTRK-fusion related neoplasms which are amenable to... 
RET | fusion | SURGERY | lipofibromatosis-like neural tumor | CARCINOMAS | NTRK | PATHOLOGY | REARRANGEMENTS | infantile fibrosarcoma | SUBSET | Sarcoma | Physiological aspects | Protein tyrosine kinase | Genetic aspects | Health aspects | Gene fusion | Proto-oncogenes
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2018, Volume 119, Issue 6, pp. 693 - 696
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 01/2019, Volume 19, Issue 1, pp. 1 - 10
Introduction: TRK fusions occur across a wide range of cancers in children and adults. These fusions drive constitutive expression and ligand-independent... 
Larotrectinib | NTRK | TRK inhibitor | TRK fusion | neurotrophin receptor | INFANTILE FIBROSARCOMA | CONGENITAL MESOBLASTIC NEPHROMA | PROTEIN-TYROSINE KINASE | TROPOMYOSIN | CANCER | RECEPTOR KINASE | ONCOLOGY | ETV6-NTRK3 GENE FUSION | THYROID-CARCINOMA | PATIENT | NTRK FUSION
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 17, pp. 13796 - 13806
Merestinib is an oral multi-kinase inhibitor targeting a limited number of oncokinases including MET, AXL, RON and MKNK1/2. Here, we report that merestinib... 
Merestinib | NTRK fusion | LY2801653 | NTRK inhibitor | Type II kinase inhibitor
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 03/2018, Volume 42, Issue 6, pp. 791 - 798
Tropomyosin receptor kinase (Trk) inhibitors have shown high response rates in patients with tumors harboring NTRK fusions. We identified 4 NTRK... 
uterine sarcoma | fibrosarcoma | NTRK | SURGERY | HYBRIDIZATION | PATHOLOGY | TUMORS | CANCER | GENE FUSIONS | DATABASE | TRK FAMILY | LOW-GRADE | RECEPTORS | ENDOMETRIAL STROMAL SARCOMA | EXPRESSION | Care and treatment | Sarcoma | Development and progression | Genetic aspects | Uterine tumors | Health aspects | Phosphotransferases | Gene fusion
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2019, Volume 30, Issue 2, pp. 325 - 331
Abstract Background NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective... 
Adult | Trk fusion cancer | Larotrectinib | Phase i | Ntrk gene fusion | larotrectinib | NTRK gene fusion | ONCOLOGY | ETV6-NTRK3 GENE FUSION | phase I | adult | TRK fusion cancer | NTRK FUSION | Original
Journal Article
Medical Oncology, ISSN 1357-0560, 06/2017, Volume 34, Issue 6, p. 1
In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy. NTRK... 
LOXO-101 | Entrectinib | NTRK mutations | NSCLC | ADVANCED SOLID TUMORS | ORAL PAN-TRK | ADENOCARCINOMA | RECEPTOR | OPEN-LABEL | CHEMOTHERAPY | EGFR | ONCOLOGY | ALK-INHIBITOR | EXPRESSION | Pharmaceutical industry | Lung cancer
Journal Article
Neuropathology, ISSN 0919-6544, 08/2018, Volume 38, Issue 4, pp. 380 - 386
Gangliogliomas are rare neoplasms of the central nervous system that mostly originate in the temporal lobe and are associated with seizures. Literature... 
targeted therapy | microarray | ganglioglioma | deletion | NTRK fusions | SOLID TUMORS | RESISTANCE | PATHOLOGY | REARRANGEMENTS | NEUROSCIENCES | CLINICAL NEUROLOGY | Cytogenetics | Genes | Temporal lobe | Genomes | Hybridization | Clonal deletion | Central nervous system | Seizures
Journal Article
Pediatric Blood and Cancer, ISSN 1545-5009, 10/2018, Volume 65, Issue 10, p. e27271
Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which... 
ETV6–NTRK | mesoplastic nephroma | larotrectinib | bone metastasis | TRK inhibitor | ONCOLOGY | INFANTILE FIBROSARCOMA | RECURRENT | ETV6-NTRK3 GENE FUSION | PEDIATRICS | ETV6-NTRK | HEMATOLOGY | INFANCY | Genetic disorders | Metastasis | Neonates | Signal transduction | Bone remodelling | Tropomyosin | Infants | Bone | Metastases
Journal Article
Oncotarget, ISSN 1949-2553, 11/2018, Volume 9, Issue 88, pp. 35809 - 35812
CGP results from >60,000 cases were screened to identify NTRK fusion events from cases of neuroendocrine tumors. 2417 NET patients from diverse anatomic sites... 
Next-generation sequencing | NTRK | NET | Neuroendocrine tumor | Neuroendocrine cancer
Journal Article
Expert Review of Clinical Pharmacology, ISSN 1751-2433, 10/2019, Volume 12, Issue 10, pp. 931 - 939
Introduction: Detecting oncogenic drivers across multiple cancers has brought about a shift toward a more targeted therapeutic approach. Neurotrophic tyrosine... 
precision oncology | Larotrectinib | TRK inhibitor | resistance | NTRK gene fusions
Journal Article
ONCOTARGETS AND THERAPY, ISSN 1178-6930, 2019, Volume 12, pp. 3171 - 3179
The development of deep-sequencing methods is now unveiling a new landscape of previously undetected gene fusion across different tumor types. Chromosomal... 
RET | TRANSFORMATION | larotrectinib | PAN-TRK | ETV6-NTRK3 | INHIBITOR ENTRECTINIB | KINASE | ACQUIRED-RESISTANCE | REARRANGEMENTS | resistance | ONCOGENE | chromosomal rearrangements | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | NTRK | CARCINOMA | Clinical trials | FDA approval | Tumors
Journal Article
The Oncologist, ISSN 1083-7159, 03/2017, Volume 22, Issue 3, pp. 255 - 263
Journal Article